SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, invites investors, analysts and media to a Capital Markets Day on September 23 in Stockholm.
The agenda and more detailed information will be announced closer to the event.
Location: GT30, Grev Turegatan 30, 114 38 Stockholm, Sweden
Date: Monday, September 23, 2024
Time: 10.00-13:00. The venue opens at 09:30.
Registration for the Capital Markets Day is made by emailing [email protected]
The last day to register is September 19, 2024.
For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: [email protected]
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.